The Central Drug Research Institute (CDRI), Lucknow is one of India's premier multidisciplinary research laboratories in the field of biomedical research, with a focus on discovering new drugs and therapeutic approaches to combat diseases of national and global importance.
Explore Our WorkEstablished in 1951, the Central Drug Research Institute (CDRI) in Lucknow, Uttar Pradesh, India, is one of the first laboratories to be established under the Council of Scientific & Industrial Research (CSIR). Over seven decades, CDRI has evolved into a globally recognized institution for drug research and development.
Our mission is to discover, develop and deliver innovative and affordable healthcare solutions through excellence in scientific research. We aim to address the unmet medical needs of India and the world, with a focus on diseases that disproportionately affect developing nations.
CDRI's research spans the entire drug discovery value chain, from basic biology and target identification to medicinal chemistry, pharmacology, toxicology, and clinical research. Our scientists work in state-of-the-art laboratories equipped with modern instrumentation and computational facilities.
To be a world-class research institute leading innovations in drug discovery and development for improved global health outcomes.
To conduct innovative research for discovery and development of novel therapeutics, diagnostics and preventive measures against diseases.
Excellence, Integrity, Collaboration, Innovation, and Commitment to Public Health.
Developing novel therapeutics for malaria, tuberculosis, HIV/AIDS, leishmaniasis, and emerging viral infections including dengue and COVID-19. Our work includes target-based drug design and repurposing existing drugs.
Research on diabetes, cardiovascular diseases, cancer, neurological disorders, and metabolic syndromes. Focus on understanding disease mechanisms and developing targeted therapies.
Investigating neuropharmacology and developing therapeutics for neurodegenerative diseases (Alzheimer's, Parkinson's), psychiatric disorders, and neuropathic pain.
Exploring India's rich biodiversity for drug discovery. Isolation, characterization, and development of bioactive compounds from medicinal plants and marine organisms.
Bridging the gap between bench and bedside through preclinical development, formulation sciences, toxicology studies, and early-phase clinical trials.
This division focuses on design, synthesis, and optimization of new chemical entities with therapeutic potential. Scientists employ computer-aided drug design, combinatorial chemistry, and structure-activity relationship studies to develop novel drug candidates.
Key Facilities: High-throughput synthesis labs, NMR spectrometry, Mass spectrometry, X-ray crystallography, Molecular modeling suite.
Head: Dr. Anil Kumar, Ph.D. (Cambridge)
This division conducts in vitro and in vivo pharmacological evaluation of new drug candidates. Research includes mechanism of action studies, safety pharmacology, and experimental therapeutics in disease models.
Key Facilities: Animal house (AAALAC accredited), Behavioral testing labs, Cardiovascular physiology lab, Isolated tissue organ baths, Cell culture facility.
Head: Dr. Priya Sharma, Ph.D., FNASc
Focuses on understanding host-pathogen interactions and developing antimicrobial agents. Research areas include bacteriology, mycology, parasitology, virology, and immunology.
Key Facilities: BSL-3 laboratory, High-content screening for antivirals, Microbial culture collection, Genomics and proteomics facility.
Head: Dr. Rajesh Verma, Ph.D. (Johns Hopkins)
Studies biochemical pathways involved in disease processes and identifies molecular targets for therapeutic intervention. Research includes enzymology, metabolomics, and signal transduction.
Key Facilities: Protein purification systems, Enzyme kinetics lab, Metabolomics platform, High-resolution mass spectrometry.
Head: Dr. Meena Kapoor, Ph.D., FASc
Journal of Medicinal Chemistry, 2024, 67(5), 3210-3225
Sharma A, Singh R, Patel S, et al. DOI: 10.1021/acs.jmedchem.3c01567
Cell Reports, 2024, 43(2), 113678
Verma P, Yadav N, Kumar D, et al. DOI: 10.1016/j.celrep.2024.113678
European Journal of Medicinal Chemistry, 2024, 265, 116098
Joshi M, Reddy K, Gupta A, et al. DOI: 10.1016/j.ejmech.2023.116098
Phytomedicine, 2024, 123, 155238
Das S, Mishra R, Tiwari P, et al. DOI: 10.1016/j.phymed.2023.155238
CDRI researchers publish extensively in high-impact international journals, contributing significantly to global scientific knowledge.
Our work has been cited over 150,000 times in the last decade.
CDRI offers exciting career opportunities for scientists, research fellows, technical staff, and administrative professionals. We provide a stimulating research environment, competitive compensation, and opportunities for professional growth.
Application deadline for current positions: May 31, 2024
CDRI offers a PhD program in collaboration with the Academy of Scientific and Innovative Research (AcSIR). Research areas include Medicinal Chemistry, Pharmacology, Microbiology, Biochemistry, and Biotechnology.
Eligibility: Master's degree in relevant discipline with valid CSIR-UGC NET/GATE score.
Stipend: ₹31,000-35,000 per month as per CSIR guidelines.
Admission Cycle: Twice yearly (January and July)
Apply NowCentral Drug Research Institute
Sector 10, Jankipuram Extension
Lucknow 226031, Uttar Pradesh, India
+91-522-2612411
+91-522-2623408 (Administration)
Administrative Office:
Monday to Friday: 9:00 AM - 5:30 PM
Saturday: 9:00 AM - 1:00 PM
Library:
Monday to Saturday: 9:00 AM - 8:00 PM
Drug License: DL-U123456-LKO-2023
Institute Code: CDRI/UP/045/CSIR